What question did this study set out to answer?

This review aims to evaluate the diagnostic accuracy and prognostic role of ctDNA-based MRD assessment after curative therapy in NSCLC.

May 18, 2026Open Access

Circulating Tumor DNA-Based Molecular Residual Disease After Curative-Intent Therapy in Non-Small Cell Lung Cancer: An Umbrella Review of Diagnostic Accuracy, Recurrence Prediction, and Adjuvant-Treatment Guidance

View Full Paper

Ask AI

Bookmark

This review aims to evaluate the diagnostic accuracy and prognostic role of ctDNA-based MRD assessment after curative therapy in NSCLC.
Synthesized evidence from systematic reviews and meta-analyses on ctDNA-MRD testing.
Utilized corrected covered area (CCA) analysis to assess evidence overlap.
Applied AMSTAR-2-informed framework to evaluate methodological quality.
ctDNA-MRD positivity correlates with higher recurrence risk and poorer survival outcomes.
Stronger prognostic value found in post-treatment and longitudinal surveillance settings.
Limitations include assay heterogeneity and reliance on observational data.

No takes yet. Share an insight, caveat, or question.

Umbrella review evaluates ctDNA-based residual disease assessment in non-small cell lung cancer, highlighting implications for treatment decisions.

Afshin Zare (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Umbrella review evaluates ctDNA-based residual disease assessment in non-small cell lung cancer, highlighting implications for treatment decisions.